|
|
| Year : 1997 | Volume
: 42
| Issue : 1 | Page : 1-8 |
|
|
Study Of Topical Anti-Inflammatory Potency And Clinical Efficacy Of Formulations Of Mometasone And Betamethasone By Cutaneous Blood Flow Measurements In Psoriatic Patients Using Laser Doppler Velocimetry
S. V Mulekar, S. S Mahajani, P. M Kulhalli, D. S Bakhle, S. S Menon
Correspondence Address:
S. V Mulekar
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Laser Doppier Velocimetry (LDV) was used to measure cutaneous blood flow (CBF) in psoriatic skin lesions to assess the effect of once daily application of Mometasone furoate (MF) in a base claimed to possess a “reservoir” effect, as against Betamethasone-17-valarate (BV) in a conventional cream base, applied twice daily, for 4 weeks. Bilaterally symmetrical active lesions were studied in 10 psoriatics, at baseline and at the end of 2 and 4 weeks’ treatment. The formulations were also evaluated for topical anti-inflammatory potency in terms of their ability to inhibit the Post-Ischaemic-Reactive-Hyperaemic-Response (PIRHR) induced on normal uninvolved skin treated under occlusion. The lesions were also assessed subjectively for clinical Psoriatic Hyperaemia Index (PHI = CBF on lesions/CBF on uninvolved skin: 8.42 + 1.74 & 10.13 + 1.70) correlating with high CPI (9 + 0.50 & 9.1 + 0.51). During treatment with MF or BV, the lesions resolved rapidly, with a concomitant decrease in PHI and CPI (Week 2 : PHI = 3.40 + 0.46 & 5.19 + 1.65, CPI = 4.15 + 0.86& 5.20 + 0.87 and Week 4 : PHI = 1.99 + 0.23 & 2.81 + 0.74 CPI = 2.00 + 0.50 & 2.88 + 0.72 respectively). The two formulations Inhibited PIRHR to same extent (auc/min: Control = 1871 + 399.22, MF = 536.11 + 153.34 & BV = 567.5 + 110.76), indicating equal potency. The results show that pharmaceutical factor such as vehicle can significantly influence the clinical efficacy of corticoids. |
|
|
|
| [PDF]* |
|
 |
|
